<?xml version="1.0" encoding="UTF-8"?>
<p id="Par2">Dopamine- and cAMP-regulated phosphoprotein of molecular weight 32 kDa (DARPP-32), also known as phosphoprotein phosphatase-1 regulatory subunit 1B (PPP1R1B), is a key molecule that integrates dopaminergic signaling into that of several other neurotransmitters, such as a glutamate
 <sup>
  <xref ref-type="bibr" rid="CR1">1</xref>
 </sup>. Phosphorylated DARPP-32 regulates the physiological activities of various proteins
 <sup>
  <xref ref-type="bibr" rid="CR2">2</xref>
 </sup>. Calcineurin (CaN) is located downstream of dopaminergic and glutamatergic signaling and inactivates DARPP-32 by dephosphorylation
 <sup>
  <xref ref-type="bibr" rid="CR3">3</xref>
 </sup>. CaN has also been associated with synaptic plasticity
 <sup>
  <xref ref-type="bibr" rid="CR4">4</xref>
 </sup> and neural cell apoptosis
 <sup>
  <xref ref-type="bibr" rid="CR5">5</xref>
 </sup>. It has been reported that the CaN inhibitor tacrolimus induces psychotic side effects such as hallucinations, anxiety, paranoid delusions, dissociative fugues, and manic-like psychosis
 <sup>
  <xref ref-type="bibr" rid="CR6">6</xref>–
  <xref ref-type="bibr" rid="CR8">8</xref>
 </sup>. Therefore, elucidating the signaling pathway that involves DARPP-32 and CaN may be critical to understanding schizophrenia and other psychiatric disorders.
</p>
